Q2: Plus Therapeutics Beats Estimates, Eos Energy Falls Short
- August 14th, 2023
- 346 views
Plus Therapeutics, Inc. (Nasdaq: PSTV), a pharmaceutical company, delivered a second-quarter 2023 loss of $(0.59) per share, surpassing the consensus estimate loss of $(1.91) per share. The company posted quarterly sales of $1.85 million, outperforming analysts' anticipated revenue of $790 thousand.
$PSTV was trading at $2.70 in after-hours, up $0.20 (+8.00%)
Meanwhile, Eos Energy Enterprises, Inc. (Nasdaq: EOSE), a player in the energy sector, reported a Q2 2023 loss of $(1.12) per share, falling short of the consensus estimate loss of $(0.37) per share. Additionally, the company generated quarterly sales of $249.00 thousand, missing analysts' projected revenue of $2.33 million for the period.
In after-hours, $EOSE was trading at $2.37, down $0.01 (-0.42%)
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
NJCP National Football Conference Names David Dalton Head Coach of Salt Lake Yeti
February 06th, 2026FDA Takes New Approach to "No Artificial Colors" Claims
February 06th, 2026NJCP National Football Conference Announces Micah Deckart as Head Coach of the Idaho Outlaws
February 05th, 2026




Member Login